Head to head
Opko Health vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: OPK · TMO
OPK
Opko Health
1.36-2.52%
1-year price shape — -10% over the period
Quant Rating D · 51/100
vs
TMO
Thermo Fisher Scientific
647.17-2.25%
1-year price shape — +23% over the period
Quant Rating C · 64/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific has the highest Quant Rating (64); Thermo Fisher Scientific has done best over the past year (+23%); Thermo Fisher Scientific pays the highest dividend yield.
| OPK | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 1.36 | 647.17 |
| Change today | -2.52% | -2.25% |
| 1-year return | -9.7% | +23.1% |
| Market cap | $1.01B | $239.29B |
| 52-week range | 0.98 – 1.75 | 434.50 – 694.33 |
| Valuation | ||
| P/E (TTM) | -19.36 | 34.83 |
| P/E percentile, own 5-yr range | 14th | 86th |
| P/B | 0.85 | 4.54 |
| Dividend yield | 0.00% | 0.28% |
| Profitability & growth | ||
| EPS (TTM) | -0.30 | 17.74 |
| Net profit (TTM) | $-223.90M | $6.56B |
| Revenue (TTM) | $587.90M | $46.34B |
| Revenue growth (YoY) | +4.3% | +10.5% |
| Gross margin | 40.8% | 40.8% |
| Operating margin | -28.6% | 18.3% |
| Net margin | -12.4% | 15.0% |
| Free cash flow (TTM) | $-134.02M | $7.32B |
| Ownership & sentiment | ||
| Institutional ownership | 34.8% | 93.1% |
| Insider activity (12mo) | 45 buy / 3 sell | 22 buy / 28 sell |
| Short interest (% of float) | 4.8% | 1.4% |
| Analyst consensus | 67% buy / 33% hold (3) | 88% buy / 12% hold (17) |
| Analyst price target | $3 (+121%) | $653 (+1%) |
| StockVane view | ||
| StockVane Quant Rating | D (51) | C (64) |
| Company | ||
| Employees | 2,275 | 125,000 |
| Founded | 1991 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.